Mesoridazine

立即咨询

Mesoridazine

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

5588-33-0

包装与价格：

包装	价格(元)
10mM (in 1mL DMSO)	电议
10mg	电议
50mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	386.57
Cas No.	5588-33-0
Formula	C₂₁H₂₆N₂OS₂
Solubility	insoluble in H2O; ≥16.35 mg/mL in DMSO; ≥3.1 mg/mL in EtOH
Chemical Name	10-(2-(1-methylpiperidin-2-yl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine
Canonical SMILES	CN1CCCCC1CCN2C3=C(C=CC(S(C)=O)=C3)SC4=C2C=CC=C4
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Mesoridazine is a dopaminergic antagonist, with aK_dvalue of 19 nM for the dopamine D2 receptor. Mesoridazine is an active metabolite of the atypical antipsychotic drug thioridazine, exhibiting stronger inhibition on pre- and postsynaptic dopamine receptors which modulate dopamine and acetylcholine release. Thus, mesoridazine is responsible for a significant part of the antidopaminergic effects attributed to thioridazine. In addition, mesoridazine also binds to histamine H1, muscarinic acetylcholine, as well as α1- and α2-adrenergic receptors, withK_dvalues being 1.8, 69, 2 and 1600 nM, respectively.

References:

1. Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. Journal of Pharmacology and Experimental Therapeutics, 1989, 250(1): 117-125.

2. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brainin vitro. European Journal of Pharmacology, 1984, 103(3-4): 197-204.

3. Shah NS. Influence of psychotropic drugs and β-diethylaminoethyl-diphenylpropylacetate (SKF 525-A) on mescaline-induced behavior and on tissue levels of mescaline in mice. Biochemical Pharmacology, 1976, 25(5): 591-597.

试验操作

Animal experiment:[3]
Animal models	Swiss-Webster albino mice, 30~33 g
Dosage form	10, 30 and 45 mg/kg Intraperitoneal Injection
Applications	Mesoridazine (10 mg/kg) did not completely abolish the locomotor activity, but did prevent the activity-increasing effect of mescaline. At high doses of 30 and 45 mg/kg, mesoridazine blocked not only the activity-increasing effect of mescaline but also the normal locomotor movements.
Note	The technical data provided above is for reference only.
	References: 1. Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. Journal of Pharmacology and Experimental Therapeutics, 1989, 250(1): 117-125. 2. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. European Journal of Pharmacology, 1984, 103(3-4): 197-204. 3. Shah NS. Influence of psychotropic drugs and β-diethylaminoethyl-diphenylpropylacetate (SKF 525-A) on mescaline-induced behavior and on tissue levels of mescaline in mice. Biochemical Pharmacology, 1976, 25(5): 591-597.